m+Medelevator.RU
← Поиск публикаций
JACC. Advances · 2025

Contemporary Management of Patients With Chagas Cardiomyopathy in Bolivia.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Czulada Evan, Bercovitch Sascha, Alshawkani Yazan, Noya Weise Natalia, Hernani Rodrigo Adriana E, Durán Saucedo Ronald Gustavo, Buhezo Chamón Marcelo, Gilman Robert H, Martin David T

Аннотация

BACKGROUND: Chagas cardiomyopathy (CCM) is the debilitating result of a parasitic infection that causes structural and electrical abnormalities. Yet, optimal CCM management is challenging in the resource-poor communities where it predominates.

OBJECTIVES: The authors sought to investigate current practice patterns and barriers to CCM care through an online survey of cardiologists in Bolivia, the country with the highest CCM prevalence.

METHODS: Cardiologists were recruited through the national cardiologist directory. The Qualtrics survey was distributed anonymously. Survey questions were developed by Bolivian and U.S. researchers with extensive Chagas disease experience.

RESULTS: Of 194 cardiologists, 67 (35%) completed ≥80% of the survey. Responses were collected from every major Bolivian city. More than 70% of cardiologists cared for CCM patients daily or weekly. More frequent prescription of angiotensin-converting enzyme inhibitors (73%) and mineralocorticoid receptor antagonists (82%) for heart failure was reported compared to β-blockers. Ventricular tachycardia treatment was achieved more often with amiodarone (92%) than implantable cardioverter-defibrillators (46%). Anticoagulation was prescribed if CCM patients had atrial fibrillation (91%) or apical aneurysm with thrombus (86%), yet few cardiologists prescribed anticoagulation in left ventricular systolic dysfunction or CCM diagnosis alone. While pacemaker therapy was generally available to cardiologists (66%), patients received devices only through private insurance or philanthropy, with few physicians (28%) offering implantable cardioverter-defibrillators regularly.

CONCLUSIONS: Cardiologists cited lack of device access as the predominant challenge in CCM management rather than insufficient knowledge or experience. These findings suggest that significant health equity gaps remain in CCM care, particularly in the availability of commonly indicated, potentially life-saving devices.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты